ABSTRACT
The use of stereotactic radiosurgery for lesions in the brain traces its origins to the pioneering work of Lars Leksell in the mid-20th century (Leksell 1951). Thousands of clinical studies since published have refined the technical aspects of SRS and patient selection criteria. Although SRS is an available treatment for certain functional disorders and selected primary brain tumors that recur after conventional therapy, the single most common application is in the treatment of brain metastases from solid tumors.
